Speakers: Richard Garr, President and CEO, Neuralstem, Inc.
Additional Information: “Clinical progress updates of Neuralstem's Phase II trial for ALS patients”
@ 5th Annual Stem Cells & Regenerative Congress
Cambridge, MA
| ROCKVILLE, Md., Nov. 12, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported financial results for the three months and nine months ended September 30, 2013 and provided a business and clinical update. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) "The Company reached several major milestones in the third quarter. We completed patient dosing in our Phase Ib trial to treat major depressive disorder with NSI-189, our lead small molecule compound. We also ... |
Sign up for Breaking News Email Alerts
